CCL20 is a potentially important component in the pathogenesis of multiple sclerosis (MS). SIRT1 exhibits a negative regulatory effect on a variety of inflammatory cytokines and can relieve experimental autoimmune encephalomyelitis. The association between the level of CCL20 and SIRT1 activity in MS patients has not been investigated. In the present study, blood samples were collected from 38 RRMS patients and 40 healthy controls. The serum CCL20 levels were measured by ELISA. SIRT1 activity was evaluated by fluorometric assay. We revealed elevated serum CCL20 concentrations in MS, and discovered an inverse correlation between CCL20 and SIRT1 activity in MS patients.
Introduction
Multiple sclerosis (MS) is a demyelinating disease characterized by chronic inflammation of the central nervous system. It has been reported that lymphocytes such as Th17 cells play key roles in the pathogenesis of MS (Jadidi-Niaragh and Mirshafiey, 2011; Rostami and Ciric, 2013) . The infiltration of lymphocytes into the CNS is an essential step in the neuropathogenesis of MS and is controlled by chemokines (Holman et al., 2011) , a group of small polypeptides that attract various leukocytes to sites of inflammation (Raman et al., 2011) . CCL20 is a highly regulated inflammatory chemokine that, via its receptor CCR6, drives the recruitment of lymphocytes, especially Th17 cells, to sites of CNS injury (Ambrosini et al., 2003; Liston et al., 2009; Reboldi et al., 2009; Yamazaki et al., 2008) . Limited evidence has shown increased serum CCL20 in MS patients (Jafarzadeh et al., 2014) . However, little is known about the expression of CCL20 in relation to the clinical characteristics of MS patients.
There is increasing evidence that epigenetic mechanisms of gene expression are involved in the regulation of proinflammatory cytokines in multiple sclerosis (Huynh and Casaccia, 2013; Kurtuncu and Tuzun, 2008) . Epigenetic control refers to several biochemical reactions in DNA that do not change its sequence, including histone acetylation, methylation, citrullination, sumoylation, and ubiquitination (Huynh and Casaccia, 2013) . Histone acetylation is catalyzed by histone acetyl transferase (HAT) while deacetylation is influenced by histone deacetylase (HDAC). SIRT1, a member of the HDAC class III family of proteins (Smith et al., 2000) , is an NAD +-dependent histone and protein deacetylase (Penberthy and Tsunoda, 2009; Smith et al., 2000) that catalyzes the removal of acetyl groups from a variety of protein substrates (Turner, 1998), including histones H1, H3, and H4 (Turner, 1998; Wang et al., 2011; Zhang and Kraus, 2010) . SIRT1 induces chromatin silencing through the deacetylation of histones (Baur, 2010) and modulates cell survival by regulating the transcriptional activities of p53 (Luo et al., 2000) , NF-κB (Yeung et al., 2004) , and FOXO proteins (Brunet et al., 2004; Motta et al., 2004) . SIRT1 exhibited negative regulatory effects on a variety of inflammatory factors, such as TNF-α and IL-8 (Lee et al., 2011; Shen et al., 2009) . A recent study demonstrated that overexpression of SIRT1 had immunomodulatory effects by reducing the numbers of IL-17-positive T cells in the white matter of spinal cord in the experimental autoimmune encephalomyelitis (EAE) model (Nimmagadda et al., 2013) . CCL20 is the major chemokine that attracts Th17 cells into the CNS; therefore, we hypothesized that SIRT1 reduces the number of central Th17 cells in EAE by inhibiting the expression of CCL20. The association between the levels of CCL20 and SIRT1 activity in MS patients has not been investigated.
Therefore, we performed a hospitalized-based study to investigate
